Flomax Risk Found for BPH Patients Facing Cataract Surgery

HoLAP is a safe, modern treatment for enlarged prostate BPHAccording to a 2009 article in Journal of the American Medical Association (JAMA), use of the medication tamsulosin (Flomax, Flomaxtra and Urimax, depending upon which nation it is sold in) to treat male urination difficulties (enlarged prostate, benign prostate hyperplasia, BPH) within two weeks of cataract surgery is associated with an increased risk of serious postoperative ophthalmic adverse events such as retinal detachment or lost lens.

Benign prostatic hyperplasia (BPH; enlarged prostate) affects nearly 3 of 4 men by the age of 70 years, with symptoms of BPH including urination difficulties. Flomax (tamsulosin) is commonly prescribed for BPH, and it had sales of more than $1 billion in 2007. Some research has suggested that this drug may increase the risk of complications, such as intraoperative floppy iris syndrome (IFIS) during cataract surgery, a procedure that approximately 5 percent of elderly U.S. residents undergo every year.

In the analysis of adverse events following cataract surgery, patients who received tamsulosin in the 14 days before surgery had a 2.3 times higher risk of a serious adverse event (7.5 percent vs. 2.7 percent of controls).

Note: Flomax copyright is owned by its owner. This website is not associated with the manufacturer or vendor of Flomax or any other product.

The opinions expressed on this website are not to be considered as medical information or advice. Every person and every situation is different. For any serious condition, you should consult qualified medical personnel. All copyrights are owned by their owners. This website is not affiliated with the manufacturer or vendor of any medical product, equipment or service.
Privacy Policy